JP2018531045A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531045A5 JP2018531045A5 JP2018536343A JP2018536343A JP2018531045A5 JP 2018531045 A5 JP2018531045 A5 JP 2018531045A5 JP 2018536343 A JP2018536343 A JP 2018536343A JP 2018536343 A JP2018536343 A JP 2018536343A JP 2018531045 A5 JP2018531045 A5 JP 2018531045A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody polypeptide
- seq
- amino acid
- light chain
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 26
- 102000004196 processed proteins & peptides Human genes 0.000 claims 26
- 108090000765 processed proteins & peptides Proteins 0.000 claims 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 206010060862 Prostate cancer Diseases 0.000 claims 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 206010027476 Metastases Diseases 0.000 claims 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical class OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 2
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 claims 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 2
- 239000002738 chelating agent Substances 0.000 claims 2
- 229960000958 deferoxamine Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 208000010658 metastatic prostate carcinoma Diseases 0.000 claims 2
- 210000004197 pelvis Anatomy 0.000 claims 2
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102000018297 Immunoglobulin subtype Human genes 0.000 claims 1
- 108050007411 Immunoglobulin subtype Proteins 0.000 claims 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 229960003330 pentetic acid Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1517550.8 | 2015-10-05 | ||
| GBGB1517550.8A GB201517550D0 (en) | 2015-10-05 | 2015-10-05 | Antibody polypeptides and uses thereof |
| GBGB1519105.9A GB201519105D0 (en) | 2015-10-29 | 2015-10-29 | Antibody polypeptides and uses thereof |
| GB1519105.9 | 2015-10-29 | ||
| PCT/EP2016/073684 WO2017060247A1 (en) | 2015-10-05 | 2016-10-04 | Humanized anti psa (5a10) antibodies |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2018531045A JP2018531045A (ja) | 2018-10-25 |
| JP2018531045A6 JP2018531045A6 (ja) | 2018-12-13 |
| JP2018531045A5 true JP2018531045A5 (https=) | 2019-11-07 |
| JP6916797B2 JP6916797B2 (ja) | 2021-08-11 |
Family
ID=57113327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018536343A Active JP6916797B2 (ja) | 2015-10-05 | 2016-10-04 | 抗体ポリペプチド及びそれらの使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11332543B2 (https=) |
| EP (2) | EP3359189B1 (https=) |
| JP (1) | JP6916797B2 (https=) |
| KR (1) | KR102783861B1 (https=) |
| CN (1) | CN108136013B (https=) |
| AU (1) | AU2016334715B2 (https=) |
| CA (1) | CA2998818A1 (https=) |
| DK (1) | DK3359189T3 (https=) |
| ES (1) | ES2880682T3 (https=) |
| IL (1) | IL258189B2 (https=) |
| LT (1) | LT3359189T (https=) |
| MX (1) | MX2018004071A (https=) |
| PL (1) | PL3359189T3 (https=) |
| PT (1) | PT3359189T (https=) |
| RU (1) | RU2753677C2 (https=) |
| WO (1) | WO2017060247A1 (https=) |
| ZA (1) | ZA201802019B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108136013B (zh) * | 2015-10-05 | 2023-04-18 | 弗雷达克斯有限责任公司 | 抗体多肽及其用途 |
| PE20191716A1 (es) | 2017-02-08 | 2019-12-05 | Bristol Myers Squibb Co | Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos |
| JP2023512214A (ja) | 2020-01-28 | 2023-03-24 | リフレクション メディカル， インコーポレイテッド | 放射性核種および外部ビーム放射線療法の共同最適化 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| FI20002127A0 (fi) * | 2000-09-27 | 2000-09-27 | Artic Partners Oy Ab | Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi |
| EP1699826B1 (en) * | 2005-01-05 | 2009-03-11 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
| US8663600B2 (en) | 2005-02-17 | 2014-03-04 | Diaprost Ab | Diagnosis of prostate cancer |
| AU2009270988A1 (en) | 2008-07-15 | 2010-01-21 | Genentech, Inc. | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds |
| JP2010004895A (ja) | 2009-10-13 | 2010-01-14 | Hiroshima Univ | ヒト化ニワトリ抗体の製造方法 |
| WO2013061083A2 (en) * | 2011-10-28 | 2013-05-02 | Fredax Ab | Therapeutic agents and uses thereof |
| RU2537263C2 (ru) | 2012-10-22 | 2014-12-27 | Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Нижегородский Государственный Университет Им. Н.И. Лобачевского" | Способ скрининга и мониторинга онкологических заболеваний и набор для его осуществления (варианты) |
| GB2520353A (en) | 2013-11-19 | 2015-05-20 | Fredax Ab | Antibody polypeptides and uses thereof |
| DK3123381T3 (da) | 2014-03-28 | 2023-11-27 | Opko Diagnostics Llc | Sammensætninger og fremgangsmåder relateret til diagnose af prostatacancer |
| CN108136013B (zh) * | 2015-10-05 | 2023-04-18 | 弗雷达克斯有限责任公司 | 抗体多肽及其用途 |
-
2016
- 2016-10-04 CN CN201680059166.8A patent/CN108136013B/zh active Active
- 2016-10-04 LT LTEPPCT/EP2016/073684T patent/LT3359189T/lt unknown
- 2016-10-04 MX MX2018004071A patent/MX2018004071A/es unknown
- 2016-10-04 PT PT167783307T patent/PT3359189T/pt unknown
- 2016-10-04 RU RU2018115734A patent/RU2753677C2/ru active
- 2016-10-04 AU AU2016334715A patent/AU2016334715B2/en active Active
- 2016-10-04 CA CA2998818A patent/CA2998818A1/en active Pending
- 2016-10-04 DK DK16778330.7T patent/DK3359189T3/da active
- 2016-10-04 IL IL258189A patent/IL258189B2/en unknown
- 2016-10-04 ES ES16778330T patent/ES2880682T3/es active Active
- 2016-10-04 PL PL16778330T patent/PL3359189T3/pl unknown
- 2016-10-04 KR KR1020187012299A patent/KR102783861B1/ko active Active
- 2016-10-04 EP EP16778330.7A patent/EP3359189B1/en active Active
- 2016-10-04 EP EP21173910.7A patent/EP3922265A1/en not_active Withdrawn
- 2016-10-04 JP JP2018536343A patent/JP6916797B2/ja active Active
- 2016-10-04 WO PCT/EP2016/073684 patent/WO2017060247A1/en not_active Ceased
- 2016-10-04 US US15/761,260 patent/US11332543B2/en active Active
-
2018
- 2018-03-27 ZA ZA2018/02019A patent/ZA201802019B/en unknown
-
2022
- 2022-04-11 US US17/717,254 patent/US12441808B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016540503A5 (https=) | ||
| JP7828375B2 (ja) | 標的分子に対する抗原結合コンストラクト | |
| Kenanova et al. | Tailoring antibodies for radionuclide delivery | |
| RU2016124229A (ru) | Полипептиды антител и их применения | |
| ES2350477T3 (es) | Internalización de anticuerpos anti-cd74 y métodos de uso. | |
| Goldenberg et al. | Cancer imaging and therapy with bispecific antibody pretargeting | |
| Navarro-Teulon et al. | General overview of radioimmunotherapy of solid tumors | |
| JP5037122B2 (ja) | 抗ｃｄ７４免疫複合体および方法 | |
| Chester et al. | Engineering antibodies for clinical applications in cancer | |
| ES2524767T3 (es) | Anticuerpo monoclonal humanizado HPAM4 | |
| Dietrich et al. | Improving external beam radiotherapy by combination with internal irradiation | |
| Jhanwar et al. | Current status of therapy of solid tumors | |
| Buchsbaum | Experimental approaches to increase radiolabeled antibody localization in tumors | |
| JP2018531045A5 (https=) | ||
| TWI908815B (zh) | 用於人類疾病之治療的ｃｄ３８抗體 | |
| Li et al. | The experimental study on the radioimmunotherapy of the nasopharyngeal carcinoma overexpressing HER2/neu in nude mice model with intratumoral injection of 188Re-herceptin | |
| Sharkey et al. | Advances in radioimmunotherapy in the age of molecular engineering and pretargeting | |
| RU2018115734A (ru) | Полипептиды антител и их применение | |
| Hauck et al. | Enhanced tumour uptake of radiolabelled antibodies by hyperthermia: Part I: Timing of injection relative to hyperthermia | |
| JP2008506355A (ja) | 抗ヒトテネイシンモノクローナル抗体 | |
| Lindegren et al. | Pretargeted radioimmunotherapy with α-particle emitting radionuclides | |
| US8728477B2 (en) | Nucleotide and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules comprising these sequences and uses thereof | |
| Vriesendorp et al. | Tumour therapy with radiolabelled antibodies: optimisation of therapy | |
| Fleckenstein et al. | Monoclonal antibodies in solid tumours: approaches to therapy with emphasis on gynaecological cancer | |
| WO2012032043A1 (en) | 212 pb imaging |